Latest / Pharmacy Podcast Network / Lipoprotein(a) and Cardiovascular Disease | Geriatric Pharmacy Focus
Transcript
- 0:05Speaker 1: You are listening to the global network of podcasters dedicated
- 0:09Speaker 1: to the pharmacy profession.
- 0:10Speaker 2: Welcome to the Pharmacy Podcast Network.
- 0:28Speaker 1: We have an aging population taking more medications than ever before.
- 0:32Speaker 1: On this podcast, I will interview experts in geriatric medicine
- 0:35Speaker 1: to gain insights so we can provide optimal care to
- 0:38Speaker 1: patients in their golden ears. I'm your host, doctor Tammer Ruggles,
- 0:41Speaker 1: and this is the Geriatric Pharmacy Focus.
- 0:47Speaker 2: Hello everyone, and welcome back to the Geriatric Pharmacy Focus.
- 0:51Speaker 2: I have been coming down the days to record this
- 0:53Speaker 2: podcast because, as you'll remember a few months ago, I
- 0:57Speaker 2: recorded the Lipid Lowdown podcast with doctor Thomas A. Spring,
- 1:00Speaker 2: and I'm delighted to have him back today. We decided
- 1:03Speaker 2: to do a deep dive into lightboprotein little A because
- 1:07Speaker 2: after we recorded the first episode, I found out indeed
- 1:11Speaker 2: I have high lightpoprotein little A and so I have
- 1:13Speaker 2: been learning so much from doctor day Spring, and I
- 1:16Speaker 2: thought you all might learn a lot too, and so
- 1:18Speaker 2: welcome doctor day Spring. It's wonderful to have you back.
- 1:22Speaker 3: Yeah, it's really nice to be back with you. You
- 1:24Speaker 3: have an amazing podcast that has a ton of followers.
- 1:27Speaker 3: So we can reach a lot of people.
- 1:29Speaker 2: Yes, and before we even start talking about lipol protein LITTLEA,
- 1:33Speaker 2: I would love it if everyone would go to familyheart
- 1:36Speaker 2: dot org and request their free kit, because it's free
- 1:39Speaker 2: and it's just a fingerpoke and you can get your
- 1:41Speaker 2: own lipel protein LITTLEA tested at no charge. So thanks
- 1:44Speaker 2: to the amazing work of familyheart dot org, please go
- 1:48Speaker 2: get your lipoprotein LITTLEA tested. So, doctor day Spring, you
- 1:52Speaker 2: have been a lipid specialist, a world renowned lipid specialist,
- 1:56Speaker 2: four years and so I recently found out about lipol
- 2:00Speaker 2: protein little A just in the last year. But when
- 2:03Speaker 2: did you first hear about lipoprotein little A and what
- 2:06Speaker 2: exactly is it?
- 2:09Speaker 3: It's a long time ago. It was discovered in nineteen
- 2:12Speaker 3: sixty three. I was in high school then, so I
- 2:15Speaker 3: knew nothing about LP little A. I doubt it was
- 2:18Speaker 3: even mentioned in medical school or during my internal medicine
- 2:22Speaker 3: residency in the mid early nineteen seventies. I started wandering
- 2:28Speaker 3: into the lipid world in the mid nineteen eighties, but
- 2:31Speaker 3: even then LP little A was not part of the discussion.
- 2:34Speaker 3: So I suspect it was. You know, after I got
- 2:38Speaker 3: involved with the National Lipid Association and started interacting with
- 2:42Speaker 3: higher level lipid specialists that it popped up on the
- 2:44Speaker 3: radar was finally starting to be measured, and so serious
- 2:50Speaker 3: lipidologists knew about it, but the real world it's really
- 2:54Speaker 3: still unknown in the real world. So I would say
- 2:57Speaker 3: right around the new millennium is when I started to
- 3:00Speaker 3: know what LP little A is and got more and
- 3:02Speaker 3: more interested in it. And in twenty twelve I left
- 3:06Speaker 3: practice to join biomarker laboratories, and it was a big
- 3:09Speaker 3: big thing in that atmosphere, of course, because they were
- 3:13Speaker 3: the labs doing all the testing and refining the diagnostics
- 3:17Speaker 3: for LP little A. And at that same time, that
- 3:20Speaker 3: was around twenty eleven twenty twelve, the first a Lipoprotein
- 3:26Speaker 3: little A Foundation was established by actually a medical professional
- 3:34Speaker 3: who herself had LP little A discovery during her pregnancy
- 3:37Speaker 3: when she had a heart attack and couldn't figure out
- 3:41Speaker 3: how a young woman could ever have a heart attack.
- 3:43Speaker 3: It stumped her doctors, but on her own know how,
- 3:46Speaker 3: she investigated and wound up doing an LP little A
- 3:49Speaker 3: test and found it is, and she was so impacted
- 3:52Speaker 3: by that she started this incredible foundation and I was
- 3:55Speaker 3: like the first guy she put on her scientific Advisory Board.
- 3:59Speaker 3: So that's my IOP little A story.
- 4:02Speaker 2: And so tell everyone what is lipoprotein little A U?
- 4:07Speaker 3: For sure, you better know what it is if you're
- 4:09Speaker 3: going to understand whatever else we're going to talk about.
- 4:11Speaker 3: So everybody knows what a low density lipoprotein or LDL is.
- 4:16Speaker 3: We've had that shoved down our throat for a long time.
- 4:19Speaker 3: That that is the blood tes you have to do
- 4:21Speaker 3: LDO cholesterol or LDO particle count because ldl's are the
- 4:25Speaker 3: primary lipoprotein. They carry cholesterol into the artery wall and
- 4:30Speaker 3: obviously start athrogenesis. So lb L particles everybody makes them.
- 4:37Speaker 3: The virtually be a rare disorder where you're not. So,
- 4:41Speaker 3: but we get all our genes from our parents, so
- 4:45Speaker 3: we always should be very careful on who we're choosing
- 4:48Speaker 3: as parents. But I don't know if we have a
- 4:50Speaker 3: choice in that. So LP LITTLEA turns out to be
- 4:54Speaker 3: the number one most frequent genetic abnormality that predisposes to
- 4:59Speaker 3: etherroskratic heart disease. So it's bad news lipoprotein. So what
- 5:04Speaker 3: it is. We all make LDL particles, But if you've
- 5:08Speaker 3: inherited the gene that goes to the liver and tells
- 5:11Speaker 3: the protein app making apparatus. Hey make this protein and
- 5:16Speaker 3: excess concentrations, and we're going to call this protein apoprotein
- 5:20Speaker 3: little A, not capital A, because APO protein capital A
- 5:25Speaker 3: is the primary APO protein that winds up on HDL particles.
- 5:29Speaker 3: So this is little A, small case little A. So
- 5:33Speaker 3: you make excess quantities of APO protein little A, it
- 5:38Speaker 3: swims across the liver side of soul and jumps on
- 5:41Speaker 3: the LDL particles that delivery is forming, and oh, now
- 5:46Speaker 3: you have an LDL particle. It's married to this APO
- 5:49Speaker 3: protein little A. Most people, if they remember our last podcast,
- 5:53Speaker 3: the only protein that's normally on an LDL particle is
- 5:57Speaker 3: APO lipoprotein B. There's one Apo B per OLDL particle,
- 6:02Speaker 3: and that is our biggest APO protein except APLE protein.
- 6:06Speaker 3: Little A can very tremendously in size. It can be
- 6:09Speaker 3: little or big. The bigger ones actually have a higher
- 6:12Speaker 3: molecular weight than Apo B. But anyway, an LDOL particle
- 6:16Speaker 3: that APO little A attaches to lycoprotein little A and
- 6:20Speaker 3: the liver just secrets it into the plasma. And we know,
- 6:24Speaker 3: just like with LDL particles, the higher the concentration, the
- 6:27Speaker 3: highest your APO B level is the higher your cardiovascular risk.
- 6:32Speaker 3: Risk related to LP little A is the same thing.
- 6:34Speaker 3: The more LP Little A particles that are cruising around
- 6:37Speaker 3: your plasma, the higher your LP Little A mediated risk.
- 6:42Speaker 3: And it's above and beyond the risk mediated by LDL particles.
- 6:46Speaker 3: So now understand, most of us we continue to make
- 6:51Speaker 3: LDO particles, those with bad genes, like you, make LP
- 6:54Speaker 3: little A particles and although they're terribly arthrogenic, actually six
- 7:00Speaker 3: to seven times more athrygenic an LP little A particle
- 7:04Speaker 3: compared to an LDO particle. We have vastly more LDOL
- 7:09Speaker 3: particles than we do LP little A particles. So, even
- 7:12Speaker 3: though they are bad news when we talk about treatment,
- 7:15Speaker 3: if we can just remove the ldol particles they're floating away,
- 7:19Speaker 3: that's right now the best way to lower risk related
- 7:22Speaker 3: to LP little A.
- 7:24Speaker 2: So when you measure a lipoprotein little A what is
- 7:27Speaker 2: considered high.
- 7:30Speaker 3: Yeah, And this is where it gets a little confusing
- 7:32Speaker 3: for people because there are two ways labs report that
- 7:36Speaker 3: are metric that they're analyzing. There. Some labs send out
- 7:40Speaker 3: what it's called a mass measurement. Basically they're removing the
- 7:44Speaker 3: LP Little A particles from a desolader of your plasma
- 7:47Speaker 3: and putting them up on a scale and weighing them by.
- 7:51Speaker 3: That's called LP little A mass. It's the weight of
- 7:54Speaker 3: all the LP little A particles in the desolat of
- 7:56Speaker 3: your plasma. So typically everybody has LPA genes but not
- 8:05Speaker 3: causing the liver to produce too much. So most of
- 8:09Speaker 3: us have trivial LP little A concentrations that are of
- 8:12Speaker 3: no clinical concern whatsoever. But as mentioned, once the particle
- 8:17Speaker 3: number starts to go up, up, up, because your liver
- 8:19Speaker 3: is way over producing a PO little A risk begins.
- 8:23Speaker 3: So if you're using LP little a mass, risk begins
- 8:27Speaker 3: above thirty milligrams per dessoleutor and it gets into the
- 8:31Speaker 3: high risk range above fifty milligrams per DESTOLEUT. I should
- 8:35Speaker 3: always say whenever we're talking about LP little A metrics,
- 8:39Speaker 3: it's highly dependent on race and ethnicity also, so some
- 8:43Speaker 3: populations lower concentrations are more scary than others. But for
- 8:48Speaker 3: most people other than African Americans, that fifty is good.
- 8:52Speaker 3: If you're an African American, pretty much above thirty milligrams
- 8:56Speaker 3: per destolet is the worrisometric. Now the other way labs
- 9:00Speaker 3: analyze and report LP little as in particle number. That
- 9:03Speaker 3: means it's a molar concentration and it's nanimal just like
- 9:07Speaker 3: ld al particles. It's nanimals per leader. So if a
- 9:11Speaker 3: lab is reporting LP little A inanimals per leader, you
- 9:15Speaker 3: start to get worried about seventy five animals per leader,
- 9:19Speaker 3: and really worried somewhere above one hundred to one hundred
- 9:21Speaker 3: and twenty five animals per leader where you start entering
- 9:25Speaker 3: the high risk zone.
- 9:28Speaker 2: So when I got my test results back, mine was
- 9:30Speaker 2: two hundred and thirty three animals per leader.
- 9:32Speaker 3: So it was the fire bells started going off when
- 9:36Speaker 3: you contacted me with that. I have a little fill
- 9:39Speaker 3: my office that when I see and that's how we
- 9:44Speaker 3: got into informing you what's necessary. You become a semi
- 9:49Speaker 3: expert on it also. So yeah, and you know, but
- 9:53Speaker 3: the good news is we can still do something for that.
- 9:56Speaker 3: And maybe the better news is in development are several
- 9:59Speaker 3: thorapeutics that would probably stop your liver from making APO
- 10:03Speaker 3: protein little A. We all believe if they can do
- 10:06Speaker 3: that safely, they will be big time winners, but they
- 10:10Speaker 3: have to do their clinical trials first.
- 10:12Speaker 2: Yeah, one thing I was surprised about is how many
- 10:14Speaker 2: people have elevated lipoprotein little light one in five worldwide
- 10:19Speaker 2: that is high or elevated.
- 10:21Speaker 3: Yes, that's why. And tragically it's not being tested. Their
- 10:24Speaker 3: doctors don't know it, and they're not testing for it,
- 10:26Speaker 3: and they're all going to wonder up why I'm getting
- 10:28Speaker 3: a stroke or a heart attack or a valve replacement
- 10:31Speaker 3: at early ages. So sad because it is so discoverable.
- 10:36Speaker 2: Especially with cardiovascular disease the number one killer in both
- 10:40Speaker 2: men and women, and so you know, anything we can
- 10:43Speaker 2: do to try to lower that risk. So we should
- 10:45Speaker 2: all get it measured, and we only need it measured
- 10:47Speaker 2: once in our lifetime, correct, because it's really not going to.
- 10:49Speaker 3: Vary much right now, that's correct, and they will say, look,
- 10:55Speaker 3: you achieve your adult levels of LP little A by
- 10:58Speaker 3: the age of five. Right now, they're just recommending that
- 11:01Speaker 3: all adults get tested for it because some of the
- 11:05Speaker 3: therapies we may suggest for doing that, we have no
- 11:07Speaker 3: data that it's important to initiate that in young children
- 11:11Speaker 3: or adolescents. So maybe one day we'll better recognize LP
- 11:15Speaker 3: little A in childhood little asterik. It is a serious
- 11:20Speaker 3: cause of stroke in children. Now that's rare stroke in
- 11:23Speaker 3: children but if a child has a stroke, it is
- 11:25Speaker 3: strongly recommended LP little A be tested. And I might say,
- 11:29Speaker 3: if you're a parent with high LP little A or
- 11:32Speaker 3: both parents, what would it hurt to get a kid
- 11:36Speaker 3: checked at an early age. You're supposed to get lipids
- 11:39Speaker 3: checked at age eight in all children to rule out
- 11:42Speaker 3: genetic LDL and other lipid disorders. So why not at
- 11:47Speaker 3: least you could for a youngster start good cardiovascular health recommendations,
- 11:53Speaker 3: the lifestyle, etc. Not that you're going to throw them
- 11:55Speaker 3: on a drug at that age, right.
- 11:58Speaker 2: Yeah, it's good to know and good to be aware,
- 12:00Speaker 2: and I agree with you. Make sure they're getting exercise,
- 12:02Speaker 2: on a healthy diet, and other ways to prevent further
- 12:06Speaker 2: in cardiovascular disease. So tell us why is this lypoprotein
- 12:10Speaker 2: little is such a big deal? What are the risks
- 12:12Speaker 2: with it?
- 12:14Speaker 3: It's been debated for a long time when it was
- 12:16Speaker 3: first discovered. Within a decade, another researcher noted that if
- 12:23Speaker 3: we look at destructure of apoprotein little A, it looks
- 12:26Speaker 3: like the structure of some of our clotting factors, especially plasminagen.
- 12:31Speaker 3: Plasminagen is involved with fibrinolysis, dissolving of clots that form
- 12:36Speaker 3: in the body, and that's part of the healing process.
- 12:39Speaker 3: When you get a clot, you form a clot, you
- 12:41Speaker 3: don't want it to stay in wherever it is forever.
- 12:44Speaker 3: Once it stops the bleeding, you want to get rid
- 12:46Speaker 3: of a clot. So that's what fibrino lisis does. But
- 12:49Speaker 3: the theory was since apoprotein little A looks as great
- 12:54Speaker 3: what we call homology, looks exactly like plasminagen, it's probably
- 12:59Speaker 3: a clot factor that inhibits fibrinolysis, and that's not good,
- 13:04Speaker 3: and that was the theory for a long time, but
- 13:06Speaker 3: right now that's almost been dismissed. Now the current belief is, yes,
- 13:13Speaker 3: LP little lake does have some coagulation effects. It can
- 13:16Speaker 3: make platelet dysfunction occur. It affects tissue factor in the blood,
- 13:21Speaker 3: which is a potent clotting factor, so there are probably
- 13:24Speaker 3: still some clotting issues related to it, but it is
- 13:27Speaker 3: now believed the primary athyrogenic process is Apoprotein little A
- 13:34Speaker 3: is like a curly Q protein. It's got a bunch
- 13:36Speaker 3: of what you know we call kringles protein loops, and
- 13:40Speaker 3: there are several of them, and actually eleven of them
- 13:45Speaker 3: in apoprotein little A and some of those kringles, and
- 13:50Speaker 3: they've identified one near the end of the protein loop
- 13:54Speaker 3: has the ability to bind two and carry what we
- 13:57Speaker 3: call oxidized phospholipp Now, any oxidized lipid is a bad news.
- 14:04Speaker 3: Lipid oxidize mean you're on fire. So you don't want
- 14:07Speaker 3: a lipid that's on fire going into any tissue in
- 14:10Speaker 3: your body, especially your artery, war because it would aggravate inflammation.
- 14:15Speaker 3: So it is often thought that maybe as we evolved,
- 14:19Speaker 3: apoprotein little A was actually a good thing. It would
- 14:22Speaker 3: bind to these oxidized, undesirable fossil lipids and bring them
- 14:27Speaker 3: back to wherever they're cleared from and get them out
- 14:29Speaker 3: of your plasma. But now, if you have a very
- 14:33Speaker 3: high concentration of LP little A, you're gonna it's gonna
- 14:37Speaker 3: pick up. And everybody creates oxidized phospholipids who's not on
- 14:41Speaker 3: the world's best lifestyle, So they're all binding to LP
- 14:46Speaker 3: little A. So if LP little A particle enters your artery, wall, hey,
- 14:51Speaker 3: it is an LVO particle carrying all the stuff they carry,
- 14:54Speaker 3: So that's not good. But it's an incredibly pro inflammatory
- 14:59Speaker 3: LP little a part article. As you know, once an
- 15:01Speaker 3: LDL particle goes into the artery wall and starts sticking together,
- 15:05Speaker 3: that's what platforms, and then the macrificer starts getting secreting
- 15:09Speaker 3: all inflammatory side of kinds and stuff. So LP little
- 15:13Speaker 3: a seemingly just worsens the inflammation that all ApoB particles
- 15:18Speaker 3: you're creating. So if I'd had my drummers, I wouldn't
- 15:23Speaker 3: want ld particles in my utery wall. But if that
- 15:25Speaker 3: were in there, I wouldn't want LP little A particles
- 15:28Speaker 3: following them in.
- 15:29Speaker 2: Yeah, so having elevated lipel protein littly is like throwing
- 15:32Speaker 2: gas on the fire pretty much.
- 15:34Speaker 3: Yeah. It's bad enough that LDLs go into our artery
- 15:38Speaker 3: walls and most people and people like you, they're going
- 15:42Speaker 3: in also, so it's a double whammy for your poor
- 15:45Speaker 3: artery wall.
- 15:46Speaker 2: I believe I listened to one of your talks for
- 15:49Speaker 2: the Family Heart and correct me if I'm wrong, But
- 15:52Speaker 2: did you mention that lipol protein littly is six times
- 15:55Speaker 2: more afrogenic than an LDL particle.
- 15:58Speaker 3: Yes, that was a great study public Slash year using
- 16:02Speaker 3: interesting techniques where they come to the conclusion that particle
- 16:07Speaker 3: for particle, an LP little A going into your r
- 16:11Speaker 3: wall versus an ld OL going into your wall. It's
- 16:13Speaker 3: I think six point six times more likely to generate
- 16:17Speaker 3: plaque than an LDOL particle. Now that's good or maybe
- 16:21Speaker 3: that's important to know, but I didn't mention earlier. All
- 16:25Speaker 3: of us have vastly more LDO particles then we do
- 16:29Speaker 3: LP little A particles. Even you bad enough you have
- 16:32Speaker 3: too many LP little A particles, but almost certainly have
- 16:35Speaker 3: more EL regular IDEO particles. So they're both bad news.
- 16:39Speaker 3: But yes, particle for particle. But because we have so
- 16:43Speaker 3: many more LDO particles, nobody should ever dismiss the athogenicity
- 16:47Speaker 3: of regular particles. We need to get rid of both
- 16:51Speaker 3: of them.
- 16:52Speaker 2: So let's say we have lipoprotein little A. What's our
- 16:56Speaker 2: treatment options?
- 16:58Speaker 3: As always with any cardiovascular risk in the lipid family,
- 17:03Speaker 3: of course, lifestyle is always an essential part of the
- 17:07Speaker 3: process because exercise, sleep, emotional health, your nutritional health, or
- 17:13Speaker 3: reduce a lot of things that aggravate athersclerosis. But they
- 17:18Speaker 3: don't know those things may even stop the production of
- 17:21Speaker 3: LDO particles. Unfortunately, with rare exception, there is no nutritional
- 17:27Speaker 3: plan that has ever been shown to seriously drop the
- 17:30Speaker 3: OLP little a concentration. There's always an anecdotal case somebody
- 17:35Speaker 3: puts on the internet, I went on this crazy diet
- 17:38Speaker 3: and I dropped my OP little a. Whatever. Good. But
- 17:42Speaker 3: that does not apply to everybody else in the population.
- 17:46Speaker 3: And if you believe it does, go do a randomized
- 17:49Speaker 3: blind that study improve it. So in general, nutrition is essential,
- 17:54Speaker 3: but if you do have high LP little a, you're
- 17:57Speaker 3: probably going to need pharmacological thirds not so much to
- 18:02Speaker 3: lower LP little a because there's only one right now
- 18:04Speaker 3: that does that, but we chase LDL particles apo B particles.
- 18:10Speaker 3: So the primary guideline suggested regiment to reduce risk if
- 18:15Speaker 3: you believe a patient has LP little a mediated risk,
- 18:18Speaker 3: is to start prescribing LDL lowering therapies. And that is
- 18:23Speaker 3: a stat and that is a zetomide, that is ben
- 18:25Speaker 3: pedoic acid, or ultimately a PCSK nine inhibitor. Those are
- 18:29Speaker 3: the four drugs we can now use to lower APO B,
- 18:33Speaker 3: which is the primary goal of therapy right now, and
- 18:38Speaker 3: we'll talk about the PCSK nine inhibitors later or whenever
- 18:42Speaker 3: you want to.
- 18:43Speaker 2: So let's say a patient is perfectly healthy, like maybe me.
- 18:48Speaker 2: For example, I don't have insular resistance or diabetes or
- 18:51Speaker 2: high blood pressure, but I have like BO protein little
- 18:53Speaker 2: A at what is it one twenty five the animals
- 18:57Speaker 2: per liter, where you would say we need to treat
- 18:59Speaker 2: you even though you have no other risk factors. Is
- 19:02Speaker 2: that kind of the number.
- 19:03Speaker 3: Yeah, that puts you in the high risk LP little
- 19:06Speaker 3: A category. So for sure you would be advised on
- 19:09Speaker 3: cardiovascular therapeutics, including all the lifestyle stuff I just mentioned,
- 19:14Speaker 3: but you would also have your APO B. If you're
- 19:18Speaker 3: not measuring apo B. People look at LDL cholesterol or
- 19:21Speaker 3: non HDO cholesterol, the latter being preferable to LDOL cholesterol
- 19:25Speaker 3: a free calculation total cholesterol minus HDL cholesterol. So if
- 19:30Speaker 3: either of those are high, guidelines would suggest getting on
- 19:34Speaker 3: the drugs I mentioned to lower LDO cholesterol non HL cholesterol.
- 19:39Speaker 3: Lipidologists like myself, we don't really look at them because
- 19:42Speaker 3: apo B is a better marker, more accurate than the
- 19:45Speaker 3: cholesterol concentrations. Most people are not doing apo B. I
- 19:49Speaker 3: would suggest they do. But if you're not, for whatever reason,
- 19:54Speaker 3: pay strict attention to non hl cholesterol and you try
- 19:57Speaker 3: and get that to goal. And that's right now, what
- 19:59Speaker 3: you can do for it, I might as well throw
- 20:02Speaker 3: it in now, because it's being used more and more.
- 20:04Speaker 3: Those PCSK nine inhibitors, I mention, they extend the residence
- 20:10Speaker 3: time of the livers LDO receptors, which is what grabs
- 20:14Speaker 3: LDEO particles, pulls them out of plasma into the liver
- 20:17Speaker 3: where they're destructed. They are our most potent drugs at
- 20:20Speaker 3: lowering APO B LDO cholesterol NONHO cholesterol. Of course, that
- 20:25Speaker 3: now that's an injectable drug every two weeks or does
- 20:28Speaker 3: a longer acting one couple times a year you can use,
- 20:31Speaker 3: but they're super expensive and third party players will not
- 20:36Speaker 3: cover a PCSK nine inhibit to treat LP litla because
- 20:41Speaker 3: it doesn't have an FDA indication to do that. So
- 20:45Speaker 3: the good news about a PCSK nine if somebody could
- 20:48Speaker 3: use that, and people who can afford six thousand dollars
- 20:51Speaker 3: a year say I'll try it, because not only does
- 20:56Speaker 3: it really it is our most significant APO B lowering drug,
- 21:00Speaker 3: but it actually can lower LP little a by about
- 21:03Speaker 3: twenty five to thirty percent. Now we don't know if
- 21:06Speaker 3: that matters, is dropping your LP littlea that much provide
- 21:10Speaker 3: any benefit the belief is it does. Some slight post
- 21:14Speaker 3: talk data from some of the PCSK nine trials suggest that, yes,
- 21:18Speaker 3: it's important, even that little bit lowering the drugs that
- 21:21Speaker 3: are coming lowering LP little a from eighty to almost
- 21:24Speaker 3: one hundred percent. So we'll see if they work. And
- 21:28Speaker 3: maybe you twenty five percent lowering is not enough, you
- 21:33Speaker 3: need more. But right now PCSK nine inhibbit is the
- 21:36Speaker 3: only thing one can use if you believe lowering LP
- 21:40Speaker 3: littlea matters. So most of the time PCSK nines are used. Now,
- 21:45Speaker 3: when a STATN or a ZOMI in a very high
- 21:48Speaker 3: risk patient doesn't get ldol cholesterol non hl cholesterol to goal,
- 21:53Speaker 3: then a third party payer would likely cover a PCSK
- 21:56Speaker 3: nine inhibitor. But somebody like yourself who doesn't have carnary
- 22:01Speaker 3: disease or really that's what you have to have to
- 22:04Speaker 3: get a PCSK nine inhibitor, it's just not going to
- 22:07Speaker 3: be improved unless you're lucky and your physician really makes
- 22:13Speaker 3: the case to the PCSK nine third party payers.
- 22:17Speaker 2: Yeah, that's held true for my treatment because I thought, well,
- 22:22Speaker 2: you know what the heck, I'll just try running it
- 22:24Speaker 2: through my insurance and see what happens, and yeah, it
- 22:27Speaker 2: was not approved. And you know, I work in a pharmacy,
- 22:30Speaker 2: so I could potentially pay cost for the medication. So
- 22:33Speaker 2: I thought, well, maybe the cost isn't so bad. But
- 22:36Speaker 2: you're right, even just the cost is over five hundred. Yeah.
- 22:39Speaker 3: And the one thing I suggest for the people high
- 22:42Speaker 3: LP little A, who I deem because I do a
- 22:44Speaker 3: total cardiovascal risk assessment maybe on LP little A two, three,
- 22:49Speaker 3: four other things. Oh my god, you know you give
- 22:53Speaker 3: them the option for PCSK nine. But listen, and it
- 22:57Speaker 3: doesn't apply to everybody, but a lot of people six
- 23:01Speaker 3: thousand dollars a year they spend that unjunk. So eliminate
- 23:05Speaker 3: some of the frivolous spending in your life and maybe
- 23:08Speaker 3: get a drug that likely can help you down the
- 23:11Speaker 3: road if you're looking for longevity and more particular health span.
- 23:15Speaker 3: So not everybody's a pharmacist who gets that discount. So
- 23:19Speaker 3: but I'm glad you did. Yeah.
- 23:22Speaker 2: So right now, for my treatment, we did start with
- 23:25Speaker 2: a stanton pluses that am We'll check my levels again
- 23:28Speaker 2: after three months and see where I'm at.
- 23:30Speaker 3: Right, And the important thing is you're going to check
- 23:33Speaker 3: your APO B non hip cholesterol level. There's no sense
- 23:37Speaker 3: even repeating your LP little A because neither of those
- 23:40Speaker 3: drugs will lower LP Little A. But the goal of
- 23:43Speaker 3: therapy until the new drugs come is get APO be
- 23:45Speaker 3: to the goal. And I let's mention this because everybody's
- 23:49Speaker 3: going to see it on the internet. Never use a
- 23:51Speaker 3: spatin because it increases LP little A. It might, and
- 23:55Speaker 3: some people you can actually get from ten to a
- 23:58Speaker 3: thirty percent increase in your LP little A particle concentration.
- 24:02Speaker 3: So if somebody like you who has a high LP
- 24:05Speaker 3: little A and it's a two hundred animals per leader,
- 24:09Speaker 3: you know you're gonna raise it by forty to fifteen
- 24:12Speaker 3: animals per leader. Maybe, but the statin is going to
- 24:17Speaker 3: lower your regular LP little A particle count by hundreds
- 24:21Speaker 3: of animals per leader. So we have some early data
- 24:25Speaker 3: that in statin trials, even though statins do nothing or
- 24:28Speaker 3: even raise LP little A, they still reduce risk in
- 24:33Speaker 3: LP little A patients. Not totally. There's still some residual risk,
- 24:38Speaker 3: but way better than if you didn't take a stat
- 24:40Speaker 3: And we now have two guidelines from the European Athroscross
- 24:44Speaker 3: Society in the National Olympic Association that strongly suggests that
- 24:49Speaker 3: you start a STAT. And if you have this, and
- 24:51Speaker 3: under no circumstances, should you ever stop a statin Because
- 24:55Speaker 3: LP little A goes up a few animals per leader?
- 24:58Speaker 3: Is that a why doesn't affect little A? So that's
- 25:01Speaker 3: not an issue, but it would certainly help a STAT
- 25:03Speaker 3: and get APO B or LDL cholesterol to goal. So
- 25:06Speaker 3: I think your choice of drugs is the initial first
- 25:09Speaker 3: step if you really got APO B to where it
- 25:12Speaker 3: should be. When I have LP little A patients, my
- 25:16Speaker 3: APO B goal becomes a little more stringent than in
- 25:19Speaker 3: people who don't have LP little A. You got to
- 25:22Speaker 3: see what look, you know, you're going to go two
- 25:24Speaker 3: three months, repeat the lab tests, and then you'll make
- 25:27Speaker 3: further decisions.
- 25:28Speaker 2: I believe my goal for apl B is less than
- 25:31Speaker 2: fifty Does that sound right?
- 25:32Speaker 3: That's what I would suggest you know, basically, if you
- 25:37Speaker 3: had significant carnary diseases on all the guidelines would tell
- 25:40Speaker 3: you get your LDLC under fifty five, and the apol
- 25:44Speaker 3: B would be right in that range. I would say
- 25:46Speaker 3: under fifty. I mean, if we knew you already had
- 25:48Speaker 3: caronary disease and we didn't mention it yet but LP
- 25:52Speaker 3: little A can also destroy the aortic valve in many people,
- 25:55Speaker 3: causing the nosis that requires surgery. So if you had
- 25:59Speaker 3: either those conditions, I don't think it's unreasonable, not easily
- 26:04Speaker 3: done sometimes is to drop that ApoB even to the
- 26:07Speaker 3: thirty range.
- 26:08Speaker 2: This kind of plays into my next question because when
- 26:11Speaker 2: I found out I had elevated lipoprotein little A, I
- 26:14Speaker 2: went and got a CAC or a coronary artery calcium
- 26:16Speaker 2: scan and that was that score was a zero, thankfully,
- 26:20Speaker 2: and my doctor, who is wonderful, thank you so much
- 26:24Speaker 2: for recommending him, checked a lot of labs and one
- 26:27Speaker 2: of them wasn't AHSCRP. So my CAP was zero. My
- 26:30Speaker 2: HSCRP was not elevated, it was less than two. And
- 26:33Speaker 2: of course through this journey, I've been posting about it
- 26:36Speaker 2: on LinkedIn, and you have those people who will message
- 26:38Speaker 2: you and say, did you see this trial where if
- 26:42Speaker 2: your CAC was zero and your AHSCRP was less than two,
- 26:46Speaker 2: your risk for cardiovascular disease isn't elevated no matter how
- 26:51Speaker 2: high your lipoprotein LITTLEA is. I've been getting a lot
- 26:54Speaker 2: of people reaching out saying you probably don't even need
- 26:56Speaker 2: to be on mids. Why are you taking a stat
- 26:58Speaker 2: and so, of course I trust you, and I trust
- 27:02Speaker 2: my doctor more than I trust myself, because you know
- 27:04Speaker 2: a heck of a lot more than I do about
- 27:06Speaker 2: this stuff. But I don't have a good response for
- 27:09Speaker 2: these people who reach out to me.
- 27:10Speaker 3: So what here's the response. Those are short trials, So
- 27:15Speaker 3: I think the risk of you having a heart attack
- 27:18Speaker 3: in the next five to ten years is very low.
- 27:21Speaker 3: But you're not ninety five years old. Now, You're going
- 27:24Speaker 3: to live a lot more than ten years. So I
- 27:27Speaker 3: would not want to tell you do no treatment and
- 27:30Speaker 3: in ten years we discover, oh, I do have athroscrosis.
- 27:33Speaker 3: Maiornic valve's got some calcium in it. Now, when the
- 27:37Speaker 3: therapy is so innocuous, are than the course of the
- 27:40Speaker 3: PCSK nine. Some people would say that's not innocuous, But
- 27:44Speaker 3: the statins and his that of mind are basically free.
- 27:47Speaker 3: They're generic drugs with very little downside. We're all well
- 27:51Speaker 3: aware of the statin downside. So if you started having
- 27:54Speaker 3: some of their side effects that aren't of frequent but
- 27:57Speaker 3: did occur, then we would switch you, probably to the
- 28:00Speaker 3: ben piedoic acid. So there's very little downside for you
- 28:05Speaker 3: to start taking drugs because I think you've a person
- 28:09Speaker 3: like yourself. You got forty fifty more years to live,
- 28:13Speaker 3: for God's sakes, and when you get to be an
- 28:15Speaker 3: old coup like me, you want to be able to
- 28:18Speaker 3: not be in heart failure, not have a valve that
- 28:21Speaker 3: needs surgery, not needs stents, God for a bit of stroke.
- 28:25Speaker 3: So why would you even take that risk when the
- 28:27Speaker 3: therapy is so innocuous? Right?
- 28:30Speaker 2: Yeah, Prevention is key. Of course, you don't have to say.
- 28:34Speaker 3: A fifty year old trial saying you never need treatment.
- 28:37Speaker 3: If at your age a carinary CAC is zero and
- 28:41Speaker 3: it was a well done okay, then I would say, yeah,
- 28:45Speaker 3: let's periodically repeat the CAC in you. But as you
- 28:49Speaker 3: know and atheroscroossis is a subclinical disease that is taking
- 28:54Speaker 3: place over decades and years in your artery wall. Since
- 28:58Speaker 3: it's totally a symptomatic and the early development of athers
- 29:02Speaker 3: grossis is not discoverable by a carnary artery calcium, you
- 29:06Speaker 3: would be more sophisticated imaging of your arteries to know
- 29:10Speaker 3: that you actually do have some plaque in your arteries
- 29:13Speaker 3: or maybe there's some LP littla particles getting into your
- 29:17Speaker 3: aortic valve, so you know it's always rolling the dice.
- 29:22Speaker 3: I call it Russian roulette to ignore treatment when you
- 29:25Speaker 3: have bad cardiovascar risk factors.
- 29:27Speaker 2: That's helpful to know, because I, of course I trust
- 29:29Speaker 2: you and your expertise, but I didn't know what to
- 29:32Speaker 2: say to some of those people who are reaching out
- 29:34Speaker 2: to me. But as far as lipel protein little A goes,
- 29:38Speaker 2: you know, a lot of people don't check it. Even
- 29:41Speaker 2: my dad when he found out his CAP score was
- 29:44Speaker 2: about five hundred, he went to a cardiologist and they
- 29:46Speaker 2: didn't check lipel protein little A or able lipeol protein B.
- 29:49Speaker 2: So why isn't lipoprotein little A routinely checked?
- 29:54Speaker 3: Number One? You will never hear that even mentioned in
- 29:56Speaker 3: medical school in residency, and we're too talking about internal
- 30:01Speaker 3: medicine residency. But even a cardiac surgeon should somewhere along
- 30:06Speaker 3: the line get some lipid treatment or so, but they don't.
- 30:10Speaker 3: Only now is some lipid information being incorporated by the
- 30:14Speaker 3: time you join a cardiac fellowship. And I know because
- 30:17Speaker 3: I'm doing a twenty part lecture series to a very
- 30:20Speaker 3: prestigious group of cardiac fellows at a university in the
- 30:24Speaker 3: United States because their leader, their program director, contacted me.
- 30:29Speaker 3: He liked my teaching style, and he says, you know,
- 30:32Speaker 3: to be honest, the cardiac fellows nowaday, they have so
- 30:35Speaker 3: much to learn. You know, cardiology is such a complex specialty,
- 30:40Speaker 3: electro cardiology, valvular heart muscle, you know, blood pressure, lipids,
- 30:46Speaker 3: arthrosclerotic sticking things in your arteries, imaging. There's so much
- 30:50Speaker 3: to learn. Lipids is like at the bottom of I
- 30:54Speaker 3: don't want to read lipid books tonight. I want to
- 30:56Speaker 3: learn how to do a pacemaker put in a stent.
- 30:59Speaker 3: So it just not taught because there's just too much
- 31:02Speaker 3: to learn. So at this university he's forcing them to
- 31:05Speaker 3: listen to me, and they're learning a lot about lippons,
- 31:08Speaker 3: including LP little A. They actually like it. So my
- 31:11Speaker 3: hope is the young group of cardiologists coming up will
- 31:14Speaker 3: be far better trained than the previous generations who it
- 31:19Speaker 3: just was not mentioned. And the sad thing is about
- 31:22Speaker 3: and I think it's a characteristic of old doctors, and
- 31:25Speaker 3: maybe more so in cardiology and absolutely in cardiac surgeons.
- 31:29Speaker 3: The egos just don't permit them to say, jeez, I
- 31:32Speaker 3: don't know anything about that. So it can't be important.
- 31:36Speaker 3: And listen, the tragedy is just go to the LP
- 31:38Speaker 3: Little A, the Family Heart Foundation. It's just not being
- 31:43Speaker 3: tested in the United States. Maybe five percent of people
- 31:47Speaker 3: get it, and yet twenty percent of humans are walking
- 31:51Speaker 3: around with it. And if nothing, because you know, I
- 31:54Speaker 3: did a lecture the other night to a group of
- 31:57Speaker 3: cardiologists in San Francisco or Southern Californian. The cardiology comes on,
- 32:02Speaker 3: why would I want to order something that's not treatable?
- 32:06Speaker 3: And he actually had no idea that the guidelines. I said,
- 32:09Speaker 3: wait a minute, the guidelines tell you how to treat
- 32:11Speaker 3: LP little A. We just told your podcast listeners how
- 32:14Speaker 3: to do it. And yeah, here's a cardiologist who didn't know.
- 32:18Speaker 3: So it just requires tremendous more education. You know where
- 32:21Speaker 3: I think it's going to get a bump. If any
- 32:23Speaker 3: of these drugs are under investigation that drastically lower LP
- 32:28Speaker 3: little A, if they have successful cardiovascer outcome trials, meaning wow,
- 32:33Speaker 3: lowering LP little A reduces heart attack strokes, valves stenosis,
- 32:37Speaker 3: they will pour a ton of money into education. And
- 32:41Speaker 3: now look, those drugs are going to be incredibly expensive.
- 32:44Speaker 3: My guess, I don't know but third party payers will
- 32:48Speaker 3: have to start covering them for people who meet the
- 32:50Speaker 3: indications that whatever the FDA puts on them. So once
- 32:55Speaker 3: it's a viable drug that might get paid by third
- 32:58Speaker 3: party payers, you're going to see a lot of education
- 33:01Speaker 3: come down on this. But more and more there are
- 33:04Speaker 3: now you go the ACC in the United States just
- 33:07Speaker 3: met this last week in Chicago. There are boosts set
- 33:12Speaker 3: up all over the place where, like you just said,
- 33:14Speaker 3: you can go in and get a free LP. Cardiologists
- 33:17Speaker 3: were lined up to get their LP A lot of
- 33:20Speaker 3: lectures of LP little A, a lot of new research
- 33:23Speaker 3: coming in on LP little A. So the learning curve
- 33:26Speaker 3: is starting to pick up. But I think if you
- 33:29Speaker 3: go to a family practitioner national meeting or internal medicine,
- 33:34Speaker 3: you know it's stuck in the back corner someplace. There
- 33:37Speaker 3: aren't forty two lectures on LP little A. So and
- 33:40Speaker 3: those are the people who are going to have to
- 33:42Speaker 3: do it. I mean, cardiologists, there's plenty of them, but
- 33:45Speaker 3: most people are not going to cards. They're going to FPS, generalists, internals,
- 33:52Speaker 3: even kind ofcologists should know about this, because God, women
- 33:56Speaker 3: have more LP little A issues than men, and it
- 33:59Speaker 3: takes off of little bit in menopause so slow, but sure,
- 34:04Speaker 3: I hope people will stalking about. You have to be
- 34:06Speaker 3: like you. You have to be your own advocate. You
- 34:10Speaker 3: have to do a little. Since you know ASCBD is
- 34:13Speaker 3: the number one cause of death globally, you have to
- 34:16Speaker 3: at a certain point start educating yourself. Are my god,
- 34:20Speaker 3: If I'm like every other human, I'm going to die
- 34:22Speaker 3: of a heart attack or stroke. And some people die
- 34:25Speaker 3: way sooner than they want to. They drop dead suddenly
- 34:29Speaker 3: because there were no warning symptoms. Let me start educating myself.
- 34:32Speaker 3: Do I have any risk factors that maybe I could
- 34:34Speaker 3: do something about? So I think patients have to start
- 34:38Speaker 3: being their own advocates. And this is where I think
- 34:42Speaker 3: you wanted to maybe discuss with me. Where do pharmacists
- 34:45Speaker 3: play a role here? Certainly the pharmacists that are interacting
- 34:49Speaker 3: with people in the pharmacy and they know who's got
- 34:54Speaker 3: cardiovaskers is because they're seeing blood pressure pills, diabetes pills,
- 35:00Speaker 3: they're seeing lipid drugs. It's not a pharmacists do a
- 35:04Speaker 3: tremendous amount of education to give into a little discussion
- 35:07Speaker 3: with people and say, oh, I see you're taking lipid drugs.
- 35:11Speaker 3: So how you're doing is everything well, are you really
- 35:14Speaker 3: being evaluated for cardiovascue disease? You know, there's this new
- 35:18Speaker 3: thing check the Family Heart Association, and it's actually as
- 35:23Speaker 3: important a risk factor as is what you're looking at
- 35:25Speaker 3: LEO cholesterol. And it's only a one time test right now,
- 35:30Speaker 3: so you might want to ask your doctor about it.
- 35:32Speaker 3: So why couldn't a pharmacist educate people? The farmdees who
- 35:36Speaker 3: are thought leaders who are visiting physicians in their office
- 35:40Speaker 3: and providing tremendous education. It's a great opportunity for them
- 35:46Speaker 3: to when they get into the lipid discussions. You know,
- 35:49Speaker 3: the farm these who are working for cardiovascular organizations can
- 35:53Speaker 3: certainly raise that and get into a real good discussion.
- 35:58Speaker 3: So I think there's endless opportunities for pharmacists in the
- 36:02Speaker 3: world nowadays to may it's part of ar mantra to
- 36:07Speaker 3: start educating people. You certainly talk to them about other
- 36:10Speaker 3: party of vascular risk factors. The people in the clinics,
- 36:13Speaker 3: So why not farm ds in many universities and even
- 36:17Speaker 3: big doctor's office are part of the therapeutic team that
- 36:20Speaker 3: are putting their heads together a strategy, so obviously they
- 36:24Speaker 3: can chine in and educate those who may not be
- 36:27Speaker 3: had this. But let's face it, you know, Tara, you're
- 36:30Speaker 3: a farm D. You just learned about OLP LITTLEA recently.
- 36:33Speaker 3: So even the farm ds. I mean, if you're a
- 36:36Speaker 3: farm D working for a pardi ofascular pharmaceutical organization, you're
- 36:39Speaker 3: gonna learn about it. But if you're a farm DS
- 36:43Speaker 3: involved with cancer drugs or signs, you may not know
- 36:46Speaker 3: about it. So somewhere in their curriculum and farm ds
- 36:50Speaker 3: go through a cardiovascular training period, it has to be mentioned.
- 36:54Speaker 3: So the professors at the university is better be aware
- 36:58Speaker 3: of this.
- 36:59Speaker 2: You bring up a good point about counseling patients. So
- 37:02Speaker 2: when I've called family members and said, look, we have
- 37:05Speaker 2: high lightbl protein little in our family, you should get
- 37:07Speaker 2: yours checked. And now when I see patients coming in
- 37:09Speaker 2: the pharmacy to pick up their cholesterol medication or their
- 37:12Speaker 2: statons and I bring it up, sometimes people will say, well,
- 37:15Speaker 2: I'm already taking a staton, so why get my wh
- 37:18Speaker 2: I get it checked? So well, would a good argument
- 37:21Speaker 2: to that.
- 37:21Speaker 3: Be that is a good question. Here's why, because we
- 37:24Speaker 3: just sort of addressed it before. If you have LP
- 37:27Speaker 3: little A, the ApoB goal of therapy becomes stricter than
- 37:31Speaker 3: it would be if you didn't. So maybe on a
- 37:33Speaker 3: STAT and you've got a decent LDO cholesterol for somebody
- 37:36Speaker 3: who's not in the higher risk categories which LP little
- 37:40Speaker 3: A puts them into, so they would want to know, Oh,
- 37:45Speaker 3: since I checked LP little A and it's kind of high,
- 37:48Speaker 3: I want my doctor and the doctor should know it himself,
- 37:51Speaker 3: but they should get into a discussion. Maybe I need
- 37:53Speaker 3: to lower LDEO cholesterol, non h L cholesterol apo B
- 37:57Speaker 3: a little more than I am currently doing. So that's
- 38:00Speaker 3: the reason why you don't say I'm on a STAT
- 38:02Speaker 3: and so I'm done. Maybe they need a zetimibe on
- 38:05Speaker 3: top of their stat and to achieve a better ApoB goal.
- 38:09Speaker 3: And if it's if they're really really high risk people
- 38:12Speaker 3: with very very high then they get into this PCSK
- 38:17Speaker 3: nine discussion with their doc and their wallet. You know you.
- 38:22Speaker 2: Mentioned the guidelines for treatment of high light protein. What
- 38:25Speaker 2: guidelines are those? Because they're not the American guidelines, are they?
- 38:30Speaker 3: Uh not? The American Heart declared LP little A a
- 38:34Speaker 3: causal risk factor for athras eurosis many years ago, when
- 38:38Speaker 3: that's a very good treatsy to read on LP little
- 38:41Speaker 3: A you'll learn a lot. But in their last national
- 38:44Speaker 3: guidelines they mentioned LP little as a risk factors, but
- 38:47Speaker 3: they're not giving you this is how you treated yourself.
- 38:51Speaker 3: So the two major guidelines that deal specifically with LP
- 38:55Speaker 3: little A, and I suggest anybody who tests and they
- 38:59Speaker 3: have LP little These are free downloadable guidelines. And in
- 39:03Speaker 3: the United States it's the National Olympic Association which diet
- 39:07Speaker 3: it in I believe twenty twenty one day updated in
- 39:11Speaker 3: twenty twenty four and the European Athlete Grosses Society I
- 39:16Speaker 3: believe has the best LP little A guidelines freely downloadable
- 39:19Speaker 3: European Heart Journal. It's worth a read now. Look, days
- 39:24Speaker 3: can be complex, but I think a layman can you
- 39:27Speaker 3: know at the end just read the conclusions. They're easy
- 39:29Speaker 3: to read. You don't have to read the high science
- 39:32Speaker 3: on it if you don't want. If you live in Canada,
- 39:34Speaker 3: Canadian guidelines also suggest once in all lifetime LP little
- 39:38Speaker 3: A testing also, So the guidelines are out there. I
- 39:42Speaker 3: think if you just googled LP little A guidelines you
- 39:46Speaker 3: would get those things. Maybe you can link them in
- 39:48Speaker 3: your podcast, and certainly they're readily available, easy to find
- 39:54Speaker 3: if you want to. And I think the best advice
- 39:58Speaker 3: for a patiental aben LA person who discovers it, zoom
- 40:02Speaker 3: over to the Family Heart Foundation, the LPA segment of that,
- 40:06Speaker 3: because they deal with other types of lipid disorders that
- 40:10Speaker 3: are not per se related to LP Little A. But
- 40:12Speaker 3: they have tremendous educational materials. Even if you need a clinician,
- 40:17Speaker 3: they can help link you up in one you you know,
- 40:22Speaker 3: we did a wonderful podcast together. We became buddies, so
- 40:25Speaker 3: you know of me and you actually say let me
- 40:28Speaker 3: check it. And you had somebody to call asap, but
- 40:31Speaker 3: not everybody. I don't practice anymore so that they can't
- 40:36Speaker 3: call me. Yeah, but it's available. The LP LITTLEA Foundation
- 40:41Speaker 3: can set you up with people that maybe in your
- 40:43Speaker 3: neighborhood who can help. And if you're smart and you
- 40:46Speaker 3: become your own advocate, there are ways of somehow bumping
- 40:50Speaker 3: into experts. Then you you might luck out.
- 40:53Speaker 2: Yeah, you did help me because we had to fire
- 40:57Speaker 2: my dad's cardiologists because he really did it know anything
- 41:02Speaker 2: about libel protein little A and I didn't feel comfortable
- 41:04Speaker 2: with my dad going in. But you did send me
- 41:06Speaker 2: a link to find a lipidologist in your area, and
- 41:09Speaker 2: so he was able to find one in his state.
- 41:12Speaker 3: That actually Listen, my joke is if you have LP
- 41:15Speaker 3: little of a God forbidding your dad, Ha's got serious
- 41:17Speaker 3: carnary disease and you walk into your cards or cardiac surgeon,
- 41:21Speaker 3: your intern's office and you say, hey, I have high
- 41:24Speaker 3: little pay or could you check it? And they say,
- 41:25Speaker 3: I don't even know what that is. I always said,
- 41:28Speaker 3: run out of that office as fast as your feet
- 41:30Speaker 3: will carry you and start finding another provider. Fortunately, more
- 41:34Speaker 3: and more knowing about it. But who would give a
- 41:37Speaker 3: patient a hard time to run a blood desk which
- 41:40Speaker 3: means nothing to the doctor. He doesn't have to pay
- 41:43Speaker 3: for it. Please, that's silly. So that's where their egos
- 41:50Speaker 3: get in the way of proper current treatment.
- 41:53Speaker 2: Right looking at cause of death, and we have cardiovascular
- 41:56Speaker 2: disease the number one cause of death and no one
- 42:00Speaker 2: really checking a lipol protein little A. But it's it's
- 42:02Speaker 2: something we need to start doing. And pharmacists can certainly
- 42:05Speaker 2: a get their own lipel protein little A checked for free,
- 42:09Speaker 2: even through the American Heart and to advocate for their
- 42:12Speaker 2: patients to get their lipoprotein little A checked. And then
- 42:15Speaker 2: the third cause of death now in the United States
- 42:18Speaker 2: is side effects. We've just moved from the fourth cause
- 42:21Speaker 2: of death to the third. And another tool we have
- 42:23Speaker 2: in our toolbox is pharmacogenomic testing, which will not only
- 42:27Speaker 2: help guide treatment for people with lipid disorders, but many
- 42:30Speaker 2: other things and prevent that third cause of death, which
- 42:33Speaker 2: is side effects. So we have two huge tools in
- 42:36Speaker 2: our toolbox by checking lipol protein LITLA and getting a
- 42:39Speaker 2: pharmacogenomic test. And by the way, both of those are
- 42:42Speaker 2: once in a lifetime, so get those checked. Because we
- 42:45Speaker 2: do mammograms and we do colonoscopies and all these other
- 42:48Speaker 2: screenings multiple times through our life. When we can do
- 42:51Speaker 2: these two once in our lifetime and prevent major causes
- 42:54Speaker 2: of death.
- 42:55Speaker 3: Yeah, I want to put one caveat where you said
- 42:58Speaker 3: the drug related deaths are number three right now, but
- 43:02Speaker 3: you're talking all drugs, you're not talking lipid drugs.
- 43:05Speaker 2: And absolutely yes.
- 43:08Speaker 3: They would be incredibly I used to have a joke
- 43:11Speaker 3: when statins first came on the market in eighty seven
- 43:14Speaker 3: and guys like me who are having people drop dead
- 43:17Speaker 3: right in the left and getting bypasses. I was obviously
- 43:21Speaker 3: became a big stat and user very quickly or so,
- 43:25Speaker 3: and you know, some people, patients wrould say, oh, I'm
- 43:29Speaker 3: so afraid of these drugs. And that continued forever even
- 43:32Speaker 3: after the proof was there. And my little joke was
- 43:36Speaker 3: all right, come on, get in my car. We're going
- 43:38Speaker 3: to drive down to the cemetery there. Now you see
- 43:40Speaker 3: all those tombstones there, Oh my god, look how many
- 43:44Speaker 3: every other one is athroscrotic heart disease. And there are
- 43:48Speaker 3: no tombstones that say died of his statin or his
- 43:51Speaker 3: lipid drugs. You got to put things in perspective. Yes,
- 43:56Speaker 3: any drug has potential side effects. Statins, as we know,
- 44:00Speaker 3: are intolerable, and some people do to muscle achs and
- 44:03Speaker 3: muscle weakness in a small minority of those who are
- 44:07Speaker 3: basically pre diabetics to begin with, you can hasten a
- 44:11Speaker 3: little bit of glucose excursion which is easily treatable or so,
- 44:15Speaker 3: so you know, you can watch your LFTs so we
- 44:21Speaker 3: can monitor those side effects. But listen, the world has changed.
- 44:24Speaker 3: And you mentioned the genomic testing. It's not only pharmica genomic,
- 44:27Speaker 3: it's cardiovascular genomics and cancer genomics. So I believe one
- 44:33Speaker 3: day or you'll just get some polygenic risk score earlier
- 44:37Speaker 3: in your life, and you even when as a kid,
- 44:40Speaker 3: you're going to know what, here's the risk of what
- 44:42Speaker 3: you're going to die from, and then you can start
- 44:44Speaker 3: taking early steps in life. And most of those early
- 44:47Speaker 3: steps is please never pick up a pack of cigarettes.
- 44:51Speaker 3: Eat better, and you know, do whatever exercise you're capable
- 44:56Speaker 3: of doing, and do that forever. And that's ultimately going
- 45:00Speaker 3: to believe bigger way to make some input on these diseases.
- 45:03Speaker 3: But I think that geno mictesting once it can, they
- 45:06Speaker 3: can really zero down on what snips are important, which
- 45:09Speaker 3: are not, which lead you off in the wrong direction.
- 45:12Speaker 3: So it is complex, but it is coming.
- 45:14Speaker 2: You're right, you bring up a valid point about Stanton's too.
- 45:18Speaker 2: Many of those side effects are dose dependent, and we know,
- 45:21Speaker 2: well I learned from you that taking a loto Stanton
- 45:24Speaker 2: plus a zenomie it can be just as effective as
- 45:27Speaker 2: taking a high dose stant with a lot less side effects.
- 45:29Speaker 2: So with that new research, maybe it's it's probably not
- 45:33Speaker 2: new to you, but it's new to me. You can
- 45:35Speaker 2: prevent a lot of side effects and still get the
- 45:37Speaker 2: amazing benefits that Stanton's have to offer.
- 45:40Speaker 3: Great point and so important for pharmacists to know, because
- 45:45Speaker 3: you know, if you're working in a drug store, patients
- 45:48Speaker 3: are coming up. I'm so afraid of my STAT and
- 45:50Speaker 3: I'm going to get side effects. You can introduce that,
- 45:53Speaker 3: you know, sometimes it's better, and of course the doc
- 45:56Speaker 3: has to make this choice, the prescribing physician. Lower those
- 46:00Speaker 3: stat and plus an incredibly safe drug, a cholesterol absorption blocker.
- 46:05Speaker 3: Is that a VIBE has the same ability to drop
- 46:08Speaker 3: apo bldo cholesterol then the maximum dose of the STAT
- 46:12Speaker 3: in which brings way more side effects as you know.
- 46:15Speaker 3: Uh so, yeah, that's far that should be in every
- 46:18Speaker 3: pharmacist's brain to at least discuss that topic with a
- 46:21Speaker 3: patient who's saying I'm so afraid of the side effects. Well,
- 46:25Speaker 3: one way is you know what a lot of drugs,
- 46:27Speaker 3: if you can use a lower dose, there's probably less
- 46:31Speaker 3: of these type of side effects or so so important
- 46:35Speaker 3: for sure.
- 46:36Speaker 2: Well, my goodness, you have taught me so much and
- 46:38Speaker 2: I feel like me and you has been one of
- 46:40Speaker 2: the biggest blessings because you've saved my life most likely
- 46:44Speaker 2: and then done so much for also my family members.
- 46:47Speaker 2: So thank you so much for all you've done for
- 46:49Speaker 2: me personally, and then just to educate everyone on lipids.
- 46:52Speaker 2: You're a truly amazing human and the world is better
- 46:55Speaker 2: because of you.
- 46:56Speaker 3: Well, thank you. I have a legacy one I guess
- 47:00Speaker 3: that I hope will say that or so. But part
- 47:02Speaker 3: of my lipid journey, and I've been everywhere, is meeting
- 47:06Speaker 3: people like yourself, both like persons but especially professionals, and
- 47:11Speaker 3: especially a professional like you. He's so respected in your
- 47:14Speaker 3: community and is so connected in your community. You can
- 47:17Speaker 3: just help spread the news, which is what you and
- 47:20Speaker 3: I do a lot of with our educational efforts. Please
- 47:24Speaker 3: my last thing is for if you're new to me,
- 47:27Speaker 3: follow me at doctor Lipid on Twitter, or if you're
- 47:31Speaker 3: a professional like join a linked connect with me on
- 47:35Speaker 3: LinkedIn and you will get all my extensive teaching materials
- 47:39Speaker 3: which I constantly post on those things and I'm blue sky.
- 47:43Speaker 3: Now that's like the newest social media.
- 47:45Speaker 2: Wow, look at you. That's amazing. And yes, please follow
- 47:48Speaker 2: doctor days Free on LinkedIn and beex The graphics that
- 47:52Speaker 2: you create to teach are so helpful in learning lipids.
- 47:56Speaker 2: That's such a complex thing to learn, but you make
- 47:57Speaker 2: the graphics that really help. So everyone follow doctor day Spring.
- 48:01Speaker 2: You're going to learn so much. Get that lifel protein,
- 48:03Speaker 2: Little A checked and thanks for listening.
- 48:06Speaker 3: Oh. I always got one more thing. The Family Heart
- 48:08Speaker 3: Foundation is doing a combined It's me and a woman
- 48:13Speaker 3: called doctor kellyannni Otis, who is a preventive neurologist who's
- 48:17Speaker 3: well schooled on brain and lipids. So the foundation is
- 48:21Speaker 3: Kelly Yann and I for an hour, hour and a
- 48:23Speaker 3: half are going to have a nice roundtable discussion just
- 48:26Speaker 3: like this on LP LITTLEA and dude, you have to
- 48:30Speaker 3: worry about your brain and lipids in the brain. So
- 48:34Speaker 3: it's free. So if you go on LinkedIn or Twitter
- 48:37Speaker 3: today you'll see the link for that, or go to
- 48:39Speaker 3: the Family Heart Association. They're tweeting that out today too,
- 48:43Speaker 3: so join us. Yeah.
- 48:45Speaker 2: I saw that this morning and I already registered because
- 48:48Speaker 2: we had doctor Josh Weigman on who talked about the
- 48:51Speaker 2: connection between lipid disorders and Alzheimer's and so I can't
- 48:54Speaker 2: wait to hear this discussion. Everyone go register. This is
- 48:57Speaker 2: going to be great.
- 48:58Speaker 3: Yeah. Jos is another rainiac as I called Kelly, And
- 49:04Speaker 1: All right, thanks everyone, have a great day.